OMass Therapeutics

University of Oxford spin-out discovering small-molecule medicines for endocrine and immunological diseases.

View on the globe

$310MEquity raised in 2025–20262025 — · 2026 $310M · 1 equity round
$410MEquity raised, all time4 equity rounds on record
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 4 rounds from 20 Nov 2018 to 15 Oct 2026, $410M equity disclosed, 2 undisclosed.20 Nov 2018: Series A, undisclosed amount; 17 Feb 2020: Extended Series A, undisclosed amount; 28 Apr 2022: Series B, $100M; 15 Oct 2026: Series C, $310M$10M$30M$100M$300M$1B2020202220242026Equity roundUndisclosed15 Oct 2026 · Series C · $310M · led by Bain Capital Life Sciences, Forbion, Novo Holdings28 Apr 2022 · Series B · $100M · led by GV, Northpond Ventures, Sanofin/d20 Nov 2018 · Series A · amount undisclosedA17 Feb 2020 · Extended Series A · amount undisclosedASeries C · $310MSeries B · $100M
Funding history: 4 rounds from 20 Nov 2018 to 15 Oct 2026, $410M equity disclosed, 2 undisclosed.20 Nov 2018: Series A, undisclosed amount; 17 Feb 2020: Extended Series A, undisclosed amount; 28 Apr 2022: Series B, $100M; 15 Oct 2026: Series C, $310M$10M$30M$100M$300M$1B2020202220242026Equity roundUndisclosed15 Oct 2026 · Series C · $310M · led by Bain Capital Life Sciences, Forbion, Novo Holdings28 Apr 2022 · Series B · $100M · led by GV, Northpond Ventures, Sanofin/d20 Nov 2018 · Series A · amount undisclosedA17 Feb 2020 · Extended Series A · amount undisclosed$310M$100M

Funding history 4 rounds · 4 sources · newest first

  1. Series C
    Amount$310MGBP 230M
    Post-money—
    ✓ Confirmed
    Lead
    Bain Capital Life Sciences, Forbion, Novo Holdings
    Also
    Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi, British Business Bank, University of Oxford
    Note
    Oversubscribed.
    Sources
  2. Series B
    Amount$100MGBP 75.5M
    Post-money—
    ✓ Confirmed
    Lead
    GV, Northpond Ventures, Sanofi
    Also
    Syncona, Oxford Science Enterprises, University of Oxford
    Note
    GBP figure converted by the company at term-sheet signing.
    Sources
  3. Extended Series A
    Amount—GBP 27.5M
    Post-money—
    ✓ Confirmed
    Lead
    Syncona, Oxford Science Enterprises
    Also
    University of Oxford
    Note
    Extension of the 2018 Series A; total Series A GBP 41.5M.
    Sources
  4. Series A
    Amount—GBP 14M
    Post-money—
    ✓ Confirmed
    Lead
    Syncona
    Also
    Oxford Science Enterprises
    Note
    Initial Series A close; Oxford Science Enterprises was then named Oxford Sciences Innovation.
    Sources

Investors 13

  • Oxford Science Enterprises4
  • Syncona4
  • GV2
  • Northpond Ventures2
  • Sanofi2
  • Bain Capital Life Sciences1
  • Forbion1
  • Novo Holdings1
  • University of Oxford3
  • British Business Bank
  • Janus Henderson Investors
  • Jefferson Life Sciences
  • SV Health Investors

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. OMass Therapeutics and its logo are trademarks of their owners, used here for identification only.